June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Effects of diquafosol sodium eye drops on tear film stability
Author Affiliations & Notes
  • Seika Den
    Ophthalmology, Tokyo Dental College, Chiba, Japan
  • Hiroyuki Iseda
    Ophthalmology, Tokyo Dental College, Chiba, Japan
  • MURAT DOGRU
    Ophthalmology, Tokyo Dental College, Chiba, Japan
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Jun Shimazaki
    Ophthalmology, Tokyo Dental College, Chiba, Japan
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • Footnotes
    Commercial Relationships Seika Den, None; Hiroyuki Iseda, None; MURAT DOGRU, Otsuka Pharmaceuticals (F); Jun Shimazaki, Santen Pharmaceutical Co. (F), Otsuka Pharmaceutical Co. (F), Abott Medical Optics (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6006. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seika Den, Hiroyuki Iseda, MURAT DOGRU, Jun Shimazaki; Effects of diquafosol sodium eye drops on tear film stability. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6006. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To investigate the effects of diquafosol sodium eye drops (DQS), a purinergic P2Y2 receptor agonist, on tear film stability in patients with unstable tear film.

 
Methods
 

Two prospective studies were conducted. One was an exploratory non-randomized trial on 39 eyes with dry eye symptoms and short tear film break-up time (BUT), but without epithelial damage. Schirmer’s test value was not considered as an inclusion or exclusion criterion. Changes in questionnaire and Visual Analog Scale (VAS) scores for symptoms, BUT, Schirmer’s value, and fluorescein staining scores of the cornea and conjunctiva were studied for 3 months. The other was a randomized clinical trial (RCT) of DQS and artificial tears in 17 eyes with short BUT. Eyes with decreased Schirmer’s values (<5mm) were excluded. Changes in symptoms, BUT, fluorescein staining score, and tear film stability using continuous corneal topographic analysis were studied for 4 weeks.

 
Results
 

In the exploratory study, significant improvements in VAS scores and BUT were noted at both 1 months (P = 0.053 and 0.0005, respectively) and 3 months (P = 0.022 and <0.0001, respectively). Schirmer’s values were not significantly increased at 1 or 3 months. Significant improvements in symptoms and BUT were more noted in eyes without decreased Schirmer’s values than in eyes with decreased Schirmer’s values. In the RCT, significant improvements in subjective symptoms were noted in the DQS groups (P = 0.0039), but not in the artificial tear group, at 2 weeks. BUT was significantly prolonged in the DQS group at 4 weeks (P = 0.029), but not in the artificial tear group. No significant changes were noted in fluorescein scores or tear film stability.

 
Conclusions
 

DQS improved subjective symptoms and prolonged BUT in eyes with unstable tear film not associated with low tear secretion and ocular surface epithelial damage. Because many patients who have unstable tear film are refractory to conventional treatments, DQS may offer benefits in the treatment of dry eyes.

 
Keywords: 486 cornea: tears/tear film/dry eye  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×